InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,011.12
(
-0.22%
)
US TECH 100
16,880.80
(
-0.33%
)
Dow Jones
37,775.38
(
0.00%
)
Brent Oil
86.00
(
-0.48%
)
Bitcoin
65,336.85
(
2.88%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 373

Sunday, 11/04/2018 12:34:46 PM

Sunday, November 04, 2018 12:34:46 PM

Post# of 438
KPTI has a lead program that aims at resistance to protease inhibitors presently used to treat Multiple Myeloma (MM)

Selinexor has been tested in combination with 4 different classes of MM drugs and has increased the efficacy of each.

4/19 PDUFA is scheduled for one of these combinations

10/18 Convertible debt offering for 150M. This plus cash makes the liklihood of dilution before the PDUFA quite low.

I have a initiated a position
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up